CBT
AIMT

Capital Bank & Trust’s Aimmune Therapeutics AIMT Stock Holding History

Capital Bank & Trust’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6
Closed – – 888
2018
Q3 		$0 Hold
6
– – ﹤0.01% 848
2018
Q2 		$0 Hold
6
– – ﹤0.01% 742
2018
Q1 		$0 Hold
6
– – ﹤0.01% 716
2017
Q4 		$0 Buy
+6
New +$194 ﹤0.01% 752

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Capital Bank & Trust's AIMT Position: Q4 2018 in Review

Capital Bank & Trust sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 6 shares.

Capital Bank & Trust first reported a position in AIMT in Q4 2017 and held it in 4 quarters. The position peaked at $0 in Q3 2018. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

  • Capital Bank & Trust reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Capital Bank & Trust sold 6 Aimmune Therapeutics shares in Q4 2018.
  • Capital Bank & Trust first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 4 quarters.
  • Capital Bank & Trust's Aimmune Therapeutics position peaked at $0 in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on Capital Bank & Trust's 13F filing for Q4 2018, filed 14 Feb 2019.